cholesterol News & Analysis

Novartis (NVS) drug trials target Lp(a) for heart disease prevention

Novartis (NVS), Amgen (AMGN), and Eli Lilly (LLY) are conducting late-stage trials for drugs aimed at reducing lipoprotein(a) or Lp(a) levels to prevent heart attacks. Current experimental drugs are shown to reduce Lp(a) by over 80%. Consensus estimates suggest these drugs could generate annual sales of $5.6 billion by 2032. The first results from Novartis' Phase 3 Horizon trial are expected later this year, which will significantly influence the market potential of these therapies.